Optimising chemoradiotherapy in anal cancer
Year: 2025
Type: article
Abstract: Concurrent chemoradiotherapy is the standard treatment for localised squamous-cell carcinoma of the anus. Even though this approach is well established, research efforts are ongoing to optimise this therapeutic option to maximise oncological outcomes, decrease treatment-related toxicity profile, and optimise health-related quality of life. We provide an overview of the available data and the active fields of research in the optimisation of chemoradiotherapy in anal cancer patients. • Concurrent chemoradiation is the standard definitive treatment in localised anal cancer. • Efforts are ongoing to optimise concurrent chemoradiation. • Personalised dose prescription, volume selection and definition and combined modality treatment are being investigated. • Risk stratification, treatment delivery and health-related quality of life are crucial topics of research. • A multidisciplinary approach is cogent.
Source: ESMO Gastrointestinal Oncology
Institutions: Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Azienda Ospedaliero Universitaria Maggiore della Carita, Ente Ospedaliero Cantonale, Istituto Oncologico della Svizzera Italiana, Università della Svizzera italiana, Oxford University Hospitals NHS Trust, University of Leeds, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Aarhus University, Aarhus University Hospital, Oslo University Hospital, University of Oslo
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4407409591